Our Stocks to Watch tomorrow include Cyclacel Pharmaceuticals Inc. (Nasdaq: CYCC), FPB Bancorp Inc. (Nasdaq: FPBI), Alkane Inc. (OTC: ALKN), Halifax Corp. of
CYCLACEL PHARMACEUTICALS INCORPORATED (NASDAQ: CYCC)
"Up 152.17% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/CYCC.php
Cyclacel is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine (CYC682), a cell cycle modulating nucleoside analog, is in Phase 2 studies for the treatment of acute myeloid leukemia in the elderly, myelodysplastic syndromes and lung cancer. The Company plans to submit a Special Protocol Assessment (SPA) request for a pivotal study with sapacitabine during the first quarter of 2010. Seliciclib (CYC202 or R-roscovitine), a CDK (cyclin dependent kinase) inhibitor, is in Phase 2 studies for the treatment of lung cancer and nasopharyngeal cancer and in a Phase 1 trial in combination with sapacitabine. CYC116, an
CYCC News:
January 7 - Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations
Seliciclib Kills Lung Cancer Cells Addicted to CDK2/Cyclin E; Phase 2 Study in Lung Cancer Ongoing
Cyclacel Pharmaceuticals, Inc. (Nasdaq: CYCC) announced the publication of two peer-reviewed journal articles featuring the company's seliciclib (CYC202 or R-roscovitine) drug candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs). CDKs have been extensively investigated as therapeutic targets in light of their frequent deregulation in lung carcinogenesis. In an article published in Clinical Cancer Research, seliciclib was found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was most effective had Ras-activating mutations. Ras is a family of mutations which make lung cancer cells highly resistant to approved drugs such as those targeting epidermal growth factor receptors (EGFR).
"Drugs that target EGFR, such as cetuximab (Erbitux®), erlotinib (Tarceva®) and gefitinib (Iressa®), are active against non-small cell lung cancer (NSCLC). However Ras family mutations, such as K-RAS and N-RAS, in NSCLC patients are associated with increased resistance to treatment. Approximately 15%-30% of patients with NSCLC harbor Ras mutations and have a poor prognosis," said Professor David Glover, Ph.D., Cyclacel's Chief Scientist. "The data published in Clinical Cancer Research show a high correlation between Ras mutations and sensitivity to seliciclib. Investigating a correlation between clinical outcomes and Ras mutation status in patients from completed seliciclib trials may provide a rationale to select patients for treatment with seliciclib or other CDK inhibitors based on mutational profile. We look forward to unblinding data from our completed Phase 2, randomized, double-blinded APPRAISE trial in patients with pretreated NSCLC during 2010. If seliciclib is found to be effective in patients with Ras-mutant NSCLC, it could address an area of high unmet medical need."
Among 52 cell lines of NSCLC origin tested, 2 (4%) were relatively insensitive to seliciclib, 21 (40%) displayed modest sensitivity and 29 (56%) showed marked sensitivity. Of the 13 lung cancer cell lines which had the highest sensitivity to seliciclib, 12 (92%) had Ras-activating mutations, including K-RAS and N-RAS. However of the 15 lung cancer cell lines which were least sensitive to seliciclib, none had Ras-activating mutations.
The Clinical Cancer Research article entitled, "Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe" reported that inhibition of CDK2 by seliciclib suppressed lung cancer growth both in vitro and in vivo of lung cancer cells addicted to CDK2/cyclin E. As a consequence, lung cancer cells underwent apoptosis or cell suicide by induction of a novel mechanism called anaphase catastrophe, as illustrated in the journal's front cover.
Combining seliciclib with microtubule-targeting agents, such as paclitaxel or docetaxel, was found to be an attractive clinical regimen to consider in patients with lung cancer. The authors also reported studying second-generation CDK inhibitors from Cyclacel with greater potency to seliciclib in terms of inhibiting the growth of lung cancer cells. Citation: Galimberti F., et. al., Clinical Cancer Research, 2010 16:1:109-120.
Seliciclib is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, double-blinded, placebo-controlled trial studying the efficacy and safety of single-agent seliciclib as a third, fourth or fifth line treatment in patients with NSCLC. The trial is using a randomized discontinuation design. The primary endpoint is progression free survival (PFS).
A second peer-reviewed article is entitled "R-roscovitine (seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis". While CDK inhibitors are known to have clinical activity against B-cell Chronic Lymphocytic Leukemia (B-CLL) cells, this publication directly compares the activity of seliciclib with commonly used therapeutic options, such as the combination of fludarabine and cyclophosphamide. In these ex vivo studies, seliciclib was compared to fludarabine and cladribine given in combination with cyclophosphamide. Seliciclib was found to be the most effective at inducing apoptosis or programmed cell death in malignant B-CLL cells while resulting in significantly less apoptosis induction in "normal" peripheral blood mononuclear cells, suggesting the largest therapeutic window among the treatments studied. Citation: Rogalinska M., et. al., Journal of Cell Biochemistry, 2010 Jan 1, 109:1:217-235.
ABOUT SELICICLIB
Seliciclib is an orally available molecule that selectively inhibits multiple CDK enzyme targets, CDK2/E, CDK2/A, CDK7 and CDK9, that are central to the process of cell division and cell cycle control. Seliciclib has been administered to approximately 420 patients in Phase 1 and Phase 2 trials. It is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, placebo-controlled, double-blinded study as a treatment in patients with non-small cell lung cancer (NSCLC) who failed at least two prior therapies and in a randomized Phase 2 study as a single agent in patients with nasopharyngeal cancer.
FPB BANCORP INCORPORATED (NASDAQ: FPBI)
"Up 150.00% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/FPBI.php
Mesa Air Group, Inc., through its subsidiaries, provides scheduled passenger and airfreight services. It carries passengers, as well as freight and express packages on its passenger flights. The company also has interlined small cargo freight agreements with various other carriers. In addition, Mesa Air Group contracts with the U.S. Postal Service for carriage of mail to the cities it serves. Further, it occasionally operates charter flights. As of September 30, 2007, the company operated a fleet of 182 aircraft with approximately 1,100 daily departures to 184 cities in the
FPBI News:
December 2 - FPB Bancorp, Inc. Commences Public Stock Offering
FPB Bancorp, Inc. (Nasdaq: FPBI), a Florida bank holding company whose subsidiary is First Peoples Bank (the "Company"), announced that it has commenced a public offering to sell units each comprised of four shares of its common stock and one warrant to purchase one share of common stock. Each unit is being sold for $6.00 and the per share warrant exercise price is $2.00. The minimum size of the offering is $5.0 million and the maximum size is approximately $25.0 million. Kendrick Pierce & Co. Securities, Inc. is acting as the exclusive placement agent for the offering.
The Company will primarily utilize the proceeds of the offering to provide capital to First Peoples Bank to maintain its capital ratios, reduce its classified assets and to support future loan and deposit growth.
FPB Bancorp, Inc. is a one bank holding company located in
ALKANE INCORPORATED (OTC: ALKN)
"Up 116.87% on Thursday"
Company Profile: http://www.otcpicks.com/alkane-inc.htm
Alkane, Inc. is dedicated to the development and sales of alternative fuels and additives which reduce the cost of operating and maintaining vehicles. Additional benefits of Alkane, Inc.'s product offerings include positive environmental impact through the reduction of harmful emissions and a lessened
ALKN News:
October 21 - Dr. Mathew Zuckerman of Alkane, Inc. Receives The Daily Record's 2009
Mathew Zuckerman, Ph.D. of Alkane, Inc. (OTC: ALKN) ("Alkane") has been selected as a winner of The Daily Record's 2009 Innovator of the Year Awards.
The Daily Record began the Innovator of the Year Awards in 2002 as a way to recognize Marylanders and Maryland-based companies for their innovative spirit - for creating new products, new programs, new services, or new processes that have helped their companies, industries, or communities.
"I am honored to have been recognized for my work on Alkane's flagship product, Monster Diesel™," said Zuckerman, who is President & CEO of Alkane, as well as Inventor of patent pending technology on which the Monster Diesel™ product is based. "We have a product that increases diesel fuel's power and MPG, lowers emissions, winterizes fuel, and reduces engine wear. It's just a matter of getting the word out to potential users. This recognition by The Daily Record helps us to do just that."
"The Daily Record's Innovators of the Year have imagination and vision, the ability to see a need and fill it, and the courage to make change happen," says Christopher Eddings, Publisher of The Daily Record. "We applaud Dr. Zuckerman for embodying the innovative spirit."
This year, The Daily Record received more than 80 nominations, which are solicited from The Daily Record's readers, economic development agencies, chambers of commerce, and the business community at large. Nominees are then asked to complete an application which explains their innovation and the impact it has made on
A distinguished panel of judges reviewed the applications and selected 25 winners for 2009, including the top Innovator of the Year. The winners were honored on October 14 at a cocktail reception, held at
ABOUT THE DAILY RECORD
For 121 years, The Daily Record Company has provided trusted legal and business information to
The Daily Record also honors leading Marylanders through events such as Influential Marylanders,
HALIFAX CORPORATION (OTC: HALX)
"Up 146.81% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/HALX.php
Founded in 1967, Halifax Corporation of
HALX News:
January 7 - Halifax Corporation of
Halifax Corporation of Virginia (OTC: HALX) announced that it had entered into a definitive agreement with Global Iron Holdings, LLC, an affiliate of Global Equity Capital, LLC, to merge with a subsidiary of Global Iron. As result of the transaction, the stockholders of
The Board of Directors of Halifax has unanimously approved the merger agreement and has recommended that
The merger is subject to approval by vote of holders of two-thirds of
Charles McNew, President and CEO, stated, "We are pleased with the all cash transaction and our ability to provide a liquidity event for our shareholders. Given the Company's limited resources, the historical cost of our SEC compliance and the challenges facing the maintenance services industry it has become apparent that affiliating ourselves with a larger, better financed organization is an appropriate step for the Company. Global Equity Capital will provide excellent positioning for continuity of our outstanding customer service and a good home for our loyal base of employees."
"Global Equity Capital is pleased to have the opportunity to provide the financial support for the acquisition, which will allow Halifax to improve its business and customer support without the pressures of being a public company," stated Angela Blatteis, Managing Director of Global Equity Capital, LLC.
The holders of the Company's $1,000,000 subordinated notes have agreed to certain modifications to the notes including extension of the maturity dates. These amendments to the outstanding notes are contingent on the merger occurring with Global Iron's subsidiary.
About Global Iron Holdings, LLC
With the support of private equity investor, Global Equity Capital, LLC, Global Iron Holdings, LLC was formed to acquire
GEN2MEDIA CORPORATION (OTCBB: GTWO)
"Up 37.59% on Thursday"
Detailed Quote: www.otcpicks.com/quotes/GTWO.php
Gen2Media is a fully integrated technology, production and marketing company whose proprietary and patent-pending technology has earned the trust of a growing, globally diversified customer base, comprised of leading media companies, corporations, chart-topping artists, entertainment companies, advertising agencies and national brands such as The Black Eyed Peas, Mary J. Blige, Britney Spears, Justin Timberlake, Microsoft Xbox LIVE, Coca-Cola Company, Toyota, Clear Channel, and others.
GTWO News:
January 7 - Gen2Media Enjoys Successful 2009; Looks Forward to 2010
Gen2Media Corporation (OTCBB: GTWO) issued an annual update to its shareholders today summarizing the milestones achieved in 2009 and the Company’s outlook for 2010.
Mark Argenti, Gen2Media CEO stated, "2009 was an incredibly rewarding and exciting year for Gen2. We successfully brought our video technology to market, landed numerous major channel partners, and built our Online Video Network faster than we initially imagined. Our entire team is thrilled with how far we have come as a Company in the past 12 months. We are extremely excited and look forward to what the next 12 months hold for Gen2."
Some of the corporate milestones attained in 2009 are:
* Successful launch of the initial version of the Gen2Media Online Video Publishing Software and exiting of beta by bringing the Online Video Platform to market
* Signing initial channel partner Emmis Communications and launching the Online Video Platform for their radio stations, including flagship stations Hot97, RXP–The NY Rock Experience, KissFM in
* Signing Tribune News Company to a contract for Gen2 to produce a daily online news show on Tribune’s Hispanic property, Hoy, located at www.vivelohoy.com. The show was produced at the Gen2 Studios and delivered via Gen2Media’s Online Video Platform to Tribune customers daily
* Launching the e360 (Entertainment 360) channel on Microsoft XBOX for delivering exclusive video content to the video game audience
* Signing Salem Communications, the leading U.S. radio broadcaster, Internet content provider, and magazine and book publisher targeting audiences interested in Christian and family-themed content and conservative values
* Signing Regent Communications to the Gen2Media Video Network to deliver online video to Regent’s 62 stations in 13 markets
* Signing over 200 radio stations to join the Gen2 Network of radio partners, and successfully migrating them to Gen2Media’s Online Video Platform
* Launching the Gen2Media Online Video Platform on select Clear Channel Stations for the delivery of original local content and advertising
* Signing a partnership agreement with Varsity brands, the definitive dance and cheerleading company in the country, and successfully migrating their millions of viewers to Varsity TV using the Gen2media Online Video Platform
* Signing a contract with FootLocker, Inc. to launch FootLocker TV online, and bring original programming to the millions of FootLocker online viewers using the Gen2 video technology and Online Video Advertising Platform
* Successfully developing and releasing Version 2 of the Gen2 Online Video Publishing Software, which includes the first of its kind
On the video production side, the Gen2 production team worked with the largest and most noted artists and venues in the world to bring cutting edge video production to live concerts worldwide including:
* The Black Eyed Peas E.N.D tour, which began in
* Producing a Documentary featuring the biggest names including Oprah, Elton John, LA Reid and many more renowned celebrities and a commercial for Mary J Blige which continues the Gen2 relationship with the iconic Grammy winning artist
* Producing all video for the Andre Agassi Foundation concert marking another remarkable year that Gen2 has provided the video technology for the Foundation
* Producing all video and media for Emmis for the renowned Summer Jam for Hot97 in Giants Stadium in
"It was obviously an action packed year for us. What we were able to accomplish is a tribute to the hard working team we have at Gen2 who serve around the clock to deliver the highest quality video technology and production for our clients and partners," noted Argenti.
Gen2Media President Mary Spio added, "2009 was an amazing year. We launched our Online Video Platform to incredible acceptance as world class names adopted our technology and model. We were also able to attract prominent advertisers like Universal Hollywood, SONY Music, Build-A-Bear and others to the Gen2 Online Video Advertising Network. We are so optimistic as we move into 2010 with this enormous momentum. Everyone in the Company looks forward to a continuing increase in network growth, customer acceptance and satisfaction, revenue and profitability. We are so thankful for all of the people that have been with us along the way. We are truly excited about the future of Gen2."
RUSSELL INDUSTRIES INCORPORATED (OTC: RIND)
"Up 33.33% on Thursday"
Detailed Quote: http://www.otcpicks.com/quotes/RIND.php
Russell Industries is a developing alternative and renewable energy company. The Company is the majority owner of 255 unpatented Uranium mining claims in
RIND News:
January 6 - Russell Industries Pilot to Scale Project Update
Russell Industries, Inc. (OTC: RIND) announced that its biofuels project is continuing on schedule. The first milestone calls for an operational pilot model to be completed by January 31, 2010.
“The prototype reactor is being used to run numerous functionality tests. On-going algae culture experiments are also being performed in concert with the engineering systems checks. Near term plans include statistical evaluation of cultures and photo-microscopic documentation of various trial runs,” said Dr. William Wilder, President of Axis Environmental Services, Inc. and scientific consultant to RIND. The Company will also be updating its website this month.
OTCPicks.com is located at
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk. You are receiving this email because you have registered on OTCPicks.com or one of our affiliate companies.
The information contained in our report should be viewed as commercial advertisement and is not intended to be investment advice. The report is not provided to any particular individual with a view toward their individual circumstances. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any company profiled based solely on information contained in our reports. Individuals should assume that all information contained in the report about profiled companies is not trustworthy unless verified by their own independent research.
Any individual who chooses to invest in any securities should do so with caution. Investing in securities is speculative and carries a high degree of risk; you may lose some or all of the money that is invested. Always research your own investments and consult with a registered investment advisor or licensed stockbroker before investing.
Information contained in our report will contain "forward looking statements" as defined under Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Subscribers are cautioned not to place undue reliance upon these forward-looking statements. These forward-looking statements are subject to a number of known and unknown risks and uncertainties outside of our control that could cause actual operations or results to differ materially from those anticipated. Factors that could affect performance include, but are not limited to, those factors that are discussed in each profiled company's most recent reports or registration statements filed with the SEC. You should consider these factors in evaluating the forward-looking statements included in the report and not place undue reliance upon such statements. We are committed to providing factual information on the companies that are profiled. However, we do not provide any assurance as to the accuracy or completeness of the information provided, including information regarding a profiled company's plans or ability to effect any planned or proposed actions. We have no first-hand knowledge of any profiled company's operations and therefore cannot comment on their capabilities, intent, resources, nor experience and we make no attempt to do so. Statistical information, dollar amounts, and market size data was provided by the subject company and related public information sources which we believe to be reliable but we cannot guarantee the accuracy of the information. To the fullest extent of the law, we will not be liable to any person or entity for the quality, accuracy, completeness, reliability, or timeliness of the information provided in the report, or for any direct, indirect, consequential, incidental, special or punitive damages that may arise out of the use of information we provide to any person or entity (including, but not limited to, lost profits, loss of opportunities, trading losses, and damages that may result from any inaccuracy or incompleteness of this information). We encourage you to invest carefully and read investment information available at the websites of the SEC at http://www.sec.gov/ and FINRA at http://www.finra.org/.
Disclosure: OTCPicks.com has been compensated two hundred and fifty thousand free trading shares by a third party (TEN Associates, LLC) for ALKN advertising and promotional services. OTCPicks.com has been compensated two thousand dollars by a third party (Blue Wave Advisors) for a one week GTWO advertising and promotional program. OTCPicks.com has been compensated ten thousand dollars by a third party (Emerging Market Consultants) for GTWO advertising and promotional services.
